We're not just envisioning the future of early disease detection—we're creating it.
Our proteomics approach offers significantly higher accuracy than existing tests. Our results are a testament to the effectiveness of our innovative approach.
Technology
Developing effective screening tests is expensive and not feasible for many diseases. Our platform allows us to radically reduce the cost of discovery and validation of novel diagnostics.
Platform
Pipelines
Two out of three global cancer deaths occur in cases where there is no effective screening test. At Novelna, we are creating a wide range of diagnostics to address this challenge.